Table 2 Candidate variants identified from recent GWAS scans for AD susceptibilitya

From: Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment

SNP

Gene

Chr.

Position (b.p.)

Minor allele frequency

Genotype × time interaction nominal P-value

Bonferroni corrected P-valueb

Pre-specified

 rs3818361

CLU

8

27 520 436

0.38

0.948

1

 rs3851179

PICALM

11

85 546 288

0.34

0.027

0.108

 rs3818361

CR1

1

205 851 591

0.22

0.933

1

 rs744373

BIN1

2

127 611 085

0.3

0.566

1

Post hoc

 rs11767557

EPHA1

7

142 819 261

0.19

0.013

0.065

 rs3865444

CD33

19

56 419 774

0.29

0.439

1

 rs3764650

ABCA7

19

997 520

0.10

0.804

1

 rs610932

MS4A6A

11

59 695 883

0.44

0.840

1

 rs670139

MS4A6A/MS4A4E

11

59 728 371

0.41

0.592

1

 rs9349407

CD2AP

6

47 561 337

NA

NA

NA

  1. Abbreviations: AD, Alzheimer's disease; CDR-SB, Clinical Dementia Rating-sum of boxes; MMSE, Mini-Mental State Examination; GWAS, genome-wide association studies; NA, not applicable; SNP, single-nucleotide polymorphism.
  2. aThe analysis was performed with experimentally obtained genotype data using change of CDR-SB as end point and a repeated mixed model to adjust for study, baseline age, gender, baseline MMSE, baseline CDR-SB and APOE ɛ4 status (+/−).
  3. bVariants in CLU, PICALM, CR1 and BIN1 were pre-specified, whereas the other recently reported variants were investigated after the primary analysis.
Back to article page